IP Library › Granted Patent US 11,541,043
Granted Patent B2
US 11,541,043 · App. 17/841,042 · Granted Jan 3, 2023

Low concentration delivery of an ergoline derivative for treatment of a headache

Inventors: Ralph Solarski (Alpharetta, GA); Robert Edward Malone (Northborough, MA)
Assignee: Relevale, Inc.
A61K31/437A61M5/2033A61M5/281A61M5/3202A61P25/06A61M2005/206A61M2005/3139
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,541,043
App. No.
17/841,042
Granted
Jan 3, 2023
Kind
B2
Abstract

Provided are ergoline derivative containing medicaments disposed within a preassembled, prefilled, single-use delivery device, methods for administering a medicament using a preassembled, prefilled, single-use delivery device, and systems or kits that contain one or more preassembled, prefilled, single-use devices and user instructions, such as for treatment of a migraine or other headache.

Claims (20)

1. A parenteral pharmaceutical composition comprising dihydroergotamine or a pharmaceutically acceptable salt thereof at a concentration of about 1 mg/mL and one or more pH maintaining or pH adjusting agents, wherein pH of the composition is between about 3 to about 5, the composition being contained in a preassembled, prefilled, single-use delivery device that is capable of delivering a dose of between about 0.5 to about 3 mg of the dihydroergotamine or the pharmaceutically acceptable salt thereof to a patient and is not user adjustable with respect to dosage or dosing rate.

2. The composition of claim 1 , wherein the one or more pH maintaining or pH adjusting agents includes a buffer.

3. The composition of claim 2 , wherein pH of the composition is maintained between 3.4 and 4.9.

4. The composition of claim 1 , wherein pH of the composition is maintained between 3.4 and 4.9.

5. The composition of claim 1 , wherein the dihydroergotamine or the pharmaceutically acceptable salt thereof is dihydroergotamine mesylate.

6. The composition of claim 5 , wherein the dose is about 1 mg of dihydroergotamine mesylate.

7. The composition of claim 6 , wherein the single-use delivery device is an autoinjector that includes a tension spring, and a rate of dosing depends on the degree of tension in the tension spring.

8. The composition of claim 7 , wherein the tension spring has a predetermined amount of tension so as to provide a desired dosing rate.

9. The composition of claim 8 , wherein the predetermined amount of tension is preloaded.

10. The composition of claim 6 , wherein the single-use delivery device is an autoinjector that includes a dosing mechanism comprising an injection spring having a degree of compression applied thereto, and a rate of dosing that depends on the degree of compression applied to the injection spring.

11. The composition of claim 10 , wherein the degree of compression of the injection spring is predetermined so as to provide a predetermined dosing rate and is not user adjustable.

12. The composition of claim 1 , wherein the one or more pH maintaining or pH adjusting agents prevent any sudden change in pH of the composition.

13. The composition of claim 1 , wherein the single-use delivery device further comprises a trigger mechanism for actuating an actuating lever maintained under pressure in an armed position.

14. The composition of claim 1 , wherein the composition is contained in the single-use delivery device by a plunger.

15. The composition of claim 1 , wherein the composition is contained in the single-use delivery device by a plunger until activated by a trigger.

16. The composition of claim 15 wherein the single-use delivery device further comprises a pawl member that releasably interfaces with a retainer in an armed position until the pawl member is released from the retainer by the trigger to activate the plunger.

17. The composition of claim 15 , wherein the trigger activates a piston rod depressing the plunger and delivering the dose through an injection needle.

18. The composition of claim 1 , wherein the single-use delivery device further comprises a moveable safety shield that is moveable about an injection needle to protect against inadvertent contact with the injection needle.

19. The composition of claim 1 , wherein the single-use delivery device further comprises a piston rod retained in an armed position keeping a tension spring under compression, the piston rod being in contact with a plunger, and when a trigger is actuated, the piston rod is released from its retainer and urged forward by the tension spring.

20. The composition of claim 1 , wherein the single-use delivery device further comprises a suction cup facilitating removal of a safety cap.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2022
From: SOLARSKI, RALPH ANDREW; MALONE, ROBERT EDWARD
To: RELEVALE, INC.
Reel/Frame 060213/0773 →
Continuity (4)
Continuation 17365750 · Jul 1, 2021
Continuation 16359313 · Mar 20, 2019
Provisional Application 62645212 · Mar 20, 2018
Related Publication 20220304991A1 · Sep 29, 2022
Cited By (2)
US 12,329,749 US 12,414,941